Extended Data Fig. 4: NRF2 transcriptional output is a molecular modifier of sotorasib efficacy in KRASG12C-mutated NSCLC.
From: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
(a) KEAP1/STK11 mutation status by NRF2 status for patients with available data (CB100 + CB200 sotorasib and docetaxel arms). (b) Prevalence of NRF2low and NRF2high tumors across KC, KL, and KP tumor types, and TTF1low or TTF1high tumors for patients with available data (CB100 + CB200 sotorasib and docetaxel arms). (c) Kaplan-Meier curve of PFS based on NRF2 activation status for patients treated with sotorasib in CB200 (left panel) or CB100 (right panel). (d) Kaplan-Meier curves of PFS (top panels) and OS (bottom panels) according to NRF2 activation status in patients treated with sotorasib or docetaxel from CB200. CB100, CodeBreaK 100; CB200, CodeBreaK 200; KRAS, Kirsten rat sarcoma virus; MUT, mutant; OS, overall survival; PFS, progression-free survival; TTF-1, thyroid transcription factor-1; WT, wild-type.
